Onconetix settles IQVIA dispute for $150k, records $0.9M reduction in accounts payable

Onconetix, Inc.

Resolved IQVIA dispute with $150k payment, avoiding claimed $1.09M liability.
Mutual release of all claims under the Master Services Agreement; no admission of liability.
Company to reduce accounts payable by approximately $0.9 million as a result of settlement.
Proteomedix subsidiary posted on LinkedIn about Proclarix study for clinically significant prostate cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.